Movement Disorders/Parkinson's Disease Program:
Active, Not Recruiting
IRB number: IRB17-0531
Title: Caffeine and other possible biomarkers in Parkinson’s disease
Site Principal Investigator: Tao Xie, MD PhD
Purpose: This study to test whether plasma or urine caffeine or its metabolites could be a biomarker of PD patients
Eligibility: Newly diagnosed PD patients not on any anti-PD medications
Funding: Michael J Fox Foundation
Contact Name: Tomas Mercado
Phone/Email: 773-702.4392 / tmercado@neurology.bsd.uchicago.edu
Status Accrual: Active, Not recruiting
Multiple Sclerosis Program
Genentech: CHORDS study, Ocrelizumab switch from failed disease-modifying drugs in RRMS. P.I., Anthony Reder; with Adil Javed, BGW Arnason, and Veronica Penyak Cipriani. Completely Enrolled.
MedDay: Effect of MD1003 (high-dose biotin) in progressive multiple sclerosis: a randomized double-blind placebo controlled study. P.I., Anthony Reder; with Adil Javed, BGW Arnason, and Veronica Penyak Cipriani. Completely Enrolled.
Biogen: AFFINITY trial, BIIB003 (Anti-LINGO) added to other MS therapies in Progressive MS. P.I., Anthony Reder; with Adil Javed, BGW Arnason, and Veronica Penyak Cipriani. Completely Enrolled.
Genentech: MN39159 CONSONANCE trial, An Open-Label, Single-Arm, 4-Year Study To Evaluate Effectiveness And Safety Of Ocrelizumab in Progressive MS. P.I., Anthony Reder; with Adil Javed, BGW Arnason, and Veronica Penyak Cipriani. Completely Enrolled.
NMO Program
Chugai: Phase I trial of an anti-IL-6 MAb in neuromyelitis optica (NMO). P.I., Adil Javed; with AT Reder, BGW Arnason, and VP Cipriani. Completely Enrolled.
MedImmune: Phase I trial of an anti-CD19 MAb in neuromyelitis optica (NMO). P.I., Adil Javed; with AT Reder, BGW Arnason, and VP Cipriani. Completely Enrolled.